// App-Quantinova.ai

4694 : ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo

Researchers

Presenter

  • Emily J. Faivre

Principal Investigators

  • Denise M. Wilcox

  • Paul Hessler

  • Tamar Uziel

  • Paul Tapang

  • Terry Magoc

  • Daniel H. Albert

  • Guowei Fang

  • Saul Rosenberg

  • Keith McDaniel

  • Warren Kati

  • Yu Shen

Medical Centers

  • AbbVie, Inc., North Chicago, IL

Locations

  • United States

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Androgen receptor variant 7

  • cMYC

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • Androgen Tear

  • abbv-075

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved